Through an international collaboration, scientists at St. Jude Children's Research Hospital leveraged data science, pharmacology and structural information to conduct an atomic-level investigation ...
Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...
Morning Overview on MSN
Light-switchable beta blocker could target tissues and cut side effects
A new class of beta blockers designed to activate only when struck by specific wavelengths of light could allow doctors to switch drug activity on and off inside targeted tissues, potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results